title: Invasive disease potential of pneumococci before and after the 13-valent pneumococcal conjugate vaccine implementation in children.
abstract: BACKGROUND
  Changes in serotype distribution have been induced after pneumococcal conjugate vaccines (PCV) implementation, and non-vaccine serotypes are now circulating. Among these latter serotypes, we aimed to distinguish those with high invasive disease potential before (2008-2009) and after PCV13 implementation (2012-2013).
  
  
  METHODS
  Invasive pneumococcal disease (IPD) serotypes isolated from children 6 to 24 months were compared with nasopharyngeal-colonizing serotypes in healthy children. To assess the invasive potential of a given serotype, odds ratios (ORs) were calculated. For each serotype, OR >1 indicated increased probability of association with IPD and OR <1 decreased probability.
  
  
  RESULTS
  In 2008/2009 and 2012/2013, 355 pneumococci were isolated from 1212 healthy children and from 569 IPD, including 166 meningitis, 114 pneumonia, and 289 other IPDs. In period 1, serotypes 7F, 3, 1, 24F, and 19A showed highly significant invasive disease potential whereas in period 2, only serotype 24F was associated with a significant high OR (6.6 [95% CI 2.6; 16.2]). Of note, for serotype 12F, OR could not be calculated because of no carrier recorded, however, if there had been a single 12F carrier, the OR would be among the highest, in period 2, 15.7 [95% 3.4; 73.0]). Only two serotypes appeared negatively associated with IPD, 11A and 23B in the period 2 as compared with nine in period 1. In the second period, pneumococcal penicillin non-susceptible isolates were mostly represented by serotypes 19A, 15A, 19F, 35B and 24F both in carriers and IPD. Only one strain was resistant to penicillin with MIC=4 μg/ml (serotype 19A) during the first period.
  
  
  CONCLUSIONS
  In children <2 years old, compared to the previous period, the number of serotypes having a high disease potential decreased after PCV13 implementation, only two non-vaccine serotypes, 24F and 12F, had high invasive disease potential.
authors.affiliation: Centre National de Référence des Pneumocoques, Laboratoire de Microbiologie, AP-HP, Hôpital Européen Georges Pompidou, Paris, France.
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: Varon
authors.affiliation: Université Paris Est, IMRB-GRC GEMINI, 94000 Créteil, France; GPIP, Groupe de Pathologie infectieuse Pédiatrique, Société Française de Pédiatrie, Nice, France; ACTIV, Association Clinique et Thérapeutique Infantile du val de Marne, Saint-Maur des Fossés, France; (54)CRC CHI Créteil, Créteil, France; Unité Court Séjour, Petits Nourrissons, Service de Néonatologie, Centre Hospitalier Intercommunal de Créteil, Créteil, France.
authors.forename: Robert
authors.initials: R
authors.lastname: Cohen
authors.affiliation: ACTIV, Association Clinique et Thérapeutique Infantile du val de Marne, Saint-Maur des Fossés, France; (54)CRC CHI Créteil, Créteil, France.
authors.forename: Stéphane
authors.initials: S
authors.lastname: Béchet
authors.affiliation: Univ Paris Diderot, Sorbonne Paris Cité, Paris, France; Service de Microbiologie, Hôpital Robert-Debré, 75019 Paris, France.
authors.forename: Catherine
authors.initials: C
authors.lastname: Doit
authors.affiliation: Université Paris Est, IMRB-GRC GEMINI, 94000 Créteil, France; GPIP, Groupe de Pathologie infectieuse Pédiatrique, Société Française de Pédiatrie, Nice, France; ACTIV, Association Clinique et Thérapeutique Infantile du val de Marne, Saint-Maur des Fossés, France; (54)CRC CHI Créteil, Créteil, France. Electronic address: corinne.levy@activ-france.fr.
authors.forename: Corinne
authors.initials: C
authors.lastname: Levy
mesh_terms: D016470:Bacteremia / Q000453:epidemiology* / Q000382:microbiology / Q000517:prevention & control; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D008586:Meningitis, Pneumococcal / Q000453:epidemiology* / Q000382:microbiology / Q000517:prevention & control; D022242:Pneumococcal Vaccines / Q000008:administration & dosage* / Q000276:immunology*; D011446:Prospective Studies; D065288:Serogroup; D013296:Streptococcus pneumoniae / Q000145:classification* / Q000302:isolation & purification*
chemical_list: C538862:13-valent pneumococcal vaccine; D022242:Pneumococcal Vaccines
keywords: 13 Valent pneumococcal conjugate vaccine; Children; Invasive disease potential; Pneumococci